Printer Friendly

CELGENE ANNOUNCES BIOTREATMENT SYSTEM FOR TOLUENE, PHENOLS AND OTHER AROMATICS

 WARREN, N.J., Nov. 19 ~PRNewswire~ -- Celgene Corporation (NASDAQ: CELG) today announced a new biotreatment system to treat toxic industrial effluents containing toluene, phenol and other aromatic compounds. The system is designed to convert these compounds into carbon dioxide at an expected treatment cost of less than $0.05 per gallon.
 The system is connected directly to the manufacturing process and can reduce concentrations of toluene or phenol in excess of 300 ppm to less than 20 ppb at effluent flow rates up to 1500 gpm. Carbon dioxide and a small amount of biomass are the only byproducts.
 "Pilot trials in Celgene's own facilities have confirmed these laboratory results," according to Dr. James Romesser, vice president of biotreatment research and development. "Our naturally occurring bacteria have achieved greater than 99 percent conversion of these compounds, which are commonly found in pharmaceutical, chemical and chemical process industry effluents."
 Romesser said a full scale demonstration is taking place at a large chemical plant in the south. "We have an effective, low-cost process and we are demonstrating the technology on a real-world effluent problem," he said.
 Celgene currently markets an in-process biotreatment system that mineralizes methylene chloride into carbon dioxide and chloride salts. That system was first demonstrated in 1991 at GE Plastics' Mt. Vernon, Ind. plant.
 Effluent biotreatment costs for toluene or phenol mineralization are expected to be in the same range as for methylene chloride which are less than $0.05 per gallon, according to Romesser. He noted that some manufacturing plants currently pay more than three times that amount to ship their effluent off-site for treatment.
 The new process is part of Celgene's continuing biotreatment development effort focused on the 11 organic and chlorinated organic compounds on the EPA's 33~50 Program list of 17 hazardous materials targeted for 50 percent industrial emission reductions by 1995.
 Celgene Corporation, based in Warren, is a chemical biotechnology company engaged in the development of proprietary biotreatment systems to degrade hazardous wastes and the development and manufacture of high- purity chiral chemicals.
 -0- 11~19~92
 ~CONTACT: R. G. Holmes, vice president and CFO of Celgene


Corporation, 908-271-1001; or Anthony J. Russo, Ph.D. or Susan Noonan of Noonan~Russo Communications, 212-979-9180, for Celgene Corporation.~
 (CELG)


CO: Celgene Corporation ST: New Jersey IN: MTC SU: PDT

AH-LR -- NY052 -- 2866 11~19~92 12:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1992
Words:391
Previous Article:PHILIPS LIGHTING ACQUIRES ELECTRONIC BALLAST TECHNOLOGY, INC.
Next Article:IMPROVED NET PROFITS AND SHAREOWNER EQUITY SHOWN IN THIRD QUARTER BY GRAYHOUND ELECTRONICS
Topics:


Related Articles
CELGENE AND GENERAL ELECTRIC DEMONSTRATE NEW TREATMENT SYSTEM TO DEGRADE TOXIC CHEMICAL WASTE
CELGENE ANNOUNCES COMPLETION OF OFFERING
CELGENE ELECTS JOHN L. UFHEIL AS CHAIRMAN; EDMUND T. PRATT JR. TO BOARD OF DIRECTORS
CELGENE APPOINTS JAMES A. ROMESSER VICE-PRESIDENT OF RESEARCH AND DEVELOPMENT
MOBIL UPGRADES BEAUMONT CHEMICAL FACILITY
CELGENE AND BETZ LABORATORIES FORM STRATEGIC ALLIANCE TO COMMERCIALIZE CELGENE'S BIOTREATMENT TECHNOLOGY
CELGENE APPOINTS JOHNSON & JOHNSON EXECUTIVE AS PRESIDENT AND COO
CELGENE CORPORATION DESIGNS AND DELIVERS NEW MOBILE REACTOR DEMONSTRATION UNIT; COMPANY ALSO EXPANDS BIOTREATMENT CAPABILITIES
SYBRON CHEMICALS INC. LICENSES BIOTREATMENT TECHNOLOGY FROM CELGENE CORPORATION
New Daily European Aromatics Report Added to CMAI's Portfolio.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters